Current Report Filing (8-k)
May 25 2021 - 11:12AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 19, 2021
Lantern
Pharma Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-39318
|
|
46-3973463
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
1920
McKinney Avenue, 7th Floor
Dallas,
Texas
|
|
75201
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(972)
277-1136
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act: Common Stock
Title
of each class
|
|
Trading
Symbol
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.0001 par value
|
|
LTRN
|
|
The
Nasdaq Stock Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company þ
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item
5.07
|
Submission
of Matters to a Vote of Security Holders.
|
On
May 19, 2021, Lantern Pharma Inc. held its 2021 Annual Meeting of Stockholders, for the purposes of:
|
●
|
Electing
six directors, each to serve until our 2022 Annual Meeting of Stockholders; and
|
|
●
|
Ratifying
the appointment of EisnerAmper LLP as our independent registered public accounting firm for
the fiscal year ending December 31, 2021.
|
All
of the persons nominated to serve on our board of directors, namely Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Leslie W. Kreis,
Jr., Franklyn Prendergast, and David S. Silberstein, were elected to our board of directors, with shares voted as follows:
Name
|
|
For
|
|
|
Withheld
|
|
|
Broker
Non-Vote
|
|
Donald Jeff Keyser
|
|
|
5,273,502
|
|
|
|
24,983
|
|
|
|
2,428,972
|
|
Panna Sharma
|
|
|
5,273,437
|
|
|
|
25,048
|
|
|
|
2,428,972
|
|
Vijay Chandru
|
|
|
5,269,729
|
|
|
|
28,756
|
|
|
|
2,428,972
|
|
Leslie W. Kreis, Jr.
|
|
|
5,269,937
|
|
|
|
28,548
|
|
|
|
2,428,972
|
|
Franklyn Prendergast
|
|
|
4,755,115
|
|
|
|
543,370
|
|
|
|
2,428,972
|
|
David S. Silberstein
|
|
|
5,273,537
|
|
|
|
24,948
|
|
|
|
2,428,972
|
|
In
addition, our stockholders ratified the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal
year ending December 31, 2021, with shares voted as follows:
For
|
|
|
7,342,520
|
|
Against
|
|
|
228,292
|
|
Abstain
|
|
|
156,645
|
|
There
were no broker non-votes on the ratification of our independent registered public accounting firm.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Lantern
Pharma Inc.,
|
|
A
Delaware Corporation
|
|
|
Dated:
May 25, 2021
|
By:
|
/s/
David R. Margrave
|
|
|
David
R. Margrave, Chief Financial Officer
|
2
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024